2022 Targeted Therapies Patient Forum

Acquired Resistance to Osimertinib in EGFR+ NSCLC

Dr. Fred Hirsch (Executive Director, Center for Thoracic Oncology at Tisch Cancer Institute, Mount Sinai, Professor of Medicine, Icahn School of Medicine, Associate Director, Biomarker Discovery for TCI)

TRANSCRIPT

Now, at that time, we classified patients as either EGFR positive or EGFR negative — we had two distinct groups. Today, we've learned that EGFR mutations are not a singular entity; within the group of EGFR mutations, we can have several types of mutations. Some of them are sensitive to the current therapy, while some of them are more resistant. Here, we can see various mutations, and I will discuss several of them.

We have also learned that when patients progress on either first, second, or third generation EGFR treatment — in this case, third generation, as I mentioned, Osimertinib — we see several other mutations potentially emerging and several pathways — we call them pathways — which means that new activated biological pathways have appeared during treatment. Is this good or bad? Well, we don't exactly know. But the positive aspect is that we have developed treatments that target specifically many of those so-called resistance mechanisms.